Eli Lilly Diabetes - Search Videos

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.

CNBCAngelica Peebles5 months ago

Eli Lilly and Company Eli Lilly Drugs List

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product

Eli Lilly is the best stock in pharma: Trader

Eli Lilly is the best stock in pharma: Trader

CNBCMelissa Lee

Full interview with Eli Lilly CEO David Ricks on emergency use authorization of Covid-19 antibody treatment

Full interview with Eli Lilly CEO David Ricks on emergency use authorization of Covid-19 antibody treatment

Top videos

Eli Lilly's Zepbound may be best-in-breed for weight loss drugs, says Dr. Kavita Patel

Eli Lilly's Zepbound may be best-in-breed for weight loss drugs, says Dr. Kavita Patel

New weight loss craze

New weight loss craze

Eli Lilly's weight loss drug almost eliminates the risk of diabetes in overweight adults

Eli Lilly's weight loss drug almost eliminates the risk of diabetes in overweight adults

Eli Lilly and Company Eli Lilly Stock Analysis

Jim Cramer: Eli Lilly stock represents real value

Jim Cramer: Eli Lilly stock represents real value

Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance

Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance

Eli Lilly CEO on the company's Q2 earnings and core business performance

Eli Lilly CEO on the company's Q2 earnings and core business performance